Eli Lilly Gets FDA OK for Onswik Once-Weekly Insulin Injection
Dow Jones18:59
Eli Lilly has won U.S. Food and Drug Administration approval for Onswik, a once-weekly basal insulin injection treatment for adults with type 2 diabetes.
Eli Lilly on Thursday said Onswik is designed to deliver steady basal insulin levels over seven days, eliminating the need for more than 300 injections a year compared to once-daily basal insulin.
The Indianapolis drugmaker said the Onswik KwikPen will be available in the U.S. in the coming months.
Onswik was previously approved for adults with type 2 diabetes in Europe, Mexico and Japan.
At the request of the copyright holder, you need to log in to view this content
Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.
Comments